Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Regulus Therapeutics Inc.
Headquarters: San Diego, CA, United States of America
Website: http://www.regulusrx.com
Year Founded: 2007
Status: Public
Industry Sector: HealthTechnology
CEO: Joseph P. Hagan, MBA
Number Of Employees: 34
Enterprise Value: $14,247,732
PE Ratio: -1.69
Exchange/Ticker 1: NASDAQ:RGLS
Exchange/Ticker 2: N/A
Latest Market Cap: $96,940,104
BioCentury | Oct 22, 2024
Product Development
Newco trend watch: Clusters of launches point to areas undergoing derisking
Oligo delivery to the kidney, and two emerging use cases for T cell engagers, each get newcos; most with mega-
BioCentury | Oct 10, 2024
Discovery & Translation
Science Spotlight: As miRNAs get Nobel Prize, targeting advances continue
BioCentury’s roundup of translational innovation also features Vedanta’s solution to GI infection, Takeda’s exon-skipping delivery tech, and more
BioCentury | Aug 23, 2024
Emerging Company Profile
Borealis: Versant, Novartis launch Chinook’s RNA-targeting sequel
The research team behind Chinook are taking on renal diseases with cell type-specific delivery of oligonucleotide therapies.
BioCentury | Mar 15, 2024
Finance
Public equity report: PIPEs for Lexicon, Cybin, Regulus, Lexeo
Companies raise cash as they eye paths forward in diabetes, depression, kidney disease and Friedreich ataxia
BioCentury | Mar 12, 2024
Product Development
Clinical report: takeaways from Amylyx’s ALS journey
Plus: A comeback for Regulus? And updates from Acadia, MoonLake, Ventyx, Acelyrin, Sanofi and more
BioCentury | Dec 16, 2022
Management Tracks
Resilience hires Rubius, Novartis vet Fisk as CTO
Plus: Seely named president and CEO at Lyell, and updates from Codagenix, Vigil, Hookipa and Cybrexa
BioCentury | Nov 3, 2021
Finance
Shoreline draws $140M to advance cell therapy pipeline
Xanthopoulos-led company now has received $300M+ from equity rounds, partnerships
BioCentury | Oct 8, 2021
Management Tracks
Doyle joins Aro as CMO
Plus: CytoDyn, HealthCap, MinervaX, Oculis and more
BioCentury | Jul 13, 2021
Management Tracks
Berkley joins AbCellera as CBO; plus Genespire, Corcept, Shoreline and more
Antibody discovery company AbCellera Biologics Inc. (NASDAQ:ABCL) hired Neil Berkley as CBO. Berkley joins from Halozyme Therapeutics Inc. (NASDAQ:HALO) where he was VP, head of business
BioCentury | May 11, 2021
Emerging Company Profile
DTx: Optimizing RNA therapies for cellular uptake, biodistribution
Emerging Company Profile: DTx is slated to enter the clinic next year with its fatty acid ligand conjugated RNA therapy to treat retinitis pigmentosa
Items per page:
1 - 10 of 161